drugset / Trial / NCT07102459

An Efficacy and Safety Study of LTG-001 Following Abdominoplasty

NCT07102459

Phase 2 Completed 343 enrolled Latigo Biotherapeutics
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The goal of this clinical trial is to learn if LTG-001 works to treat post-operative / acute pain after an abdominoplasty procedure. It will also learn more information on the safety of LTG-001. The main questions it aims to answer are: Does drug LTG-001 treat the acute pain after surgical abdominoplasty over 48 hours? How tolerable is LTG-001 over 48 hours? What dose of LTG-001 is better for treating post-operative / acute pain? Participants will: Take LTG-001 bid after the surgical abdominoplasty. Remain at the clinic for approximately 48 hours during study dosing and return after two weeks for a safety check up. Report the pain relief during the 48 hours to record changes in the post-operative pain.

Timeline

Start
2025-07-24
Primary completion
2026-01-07
Completion
2026-01-07

Drugs

EvaluationDrugModalityDoseRoute
Comparator Acetaminophen Small molecule
Subject LTG-001 Unknown

Indications

No indication recorded.